Takayo Murase

TL;DR: In this paper, a cross-sectional study examined whether uric acid possesses effects on oxidative stress under physiological conditions independent of xanthine oxidoreductase (XOR), which is involved in uric acids and ROS production.

TL;DR: Xanthine oxidoreductase (XOR) inhibitor administration reduces uric acid and reactive oxygen species (ROS) production, and also lowers blood pressure (BP), but the associations of plasma XOR activity, uric Acid level, and oxidative stress levels with BP remain unclear.

TL;DR: It is suggested that glycemic control in hemodialysis patients may be important in regard to a decrease in ROS induced by XOR, as well as factors associated with plasma XOR-a, in those without type 2 diabetes mellitus.

TL;DR: Plasma XOR activity was found to be positively associated with serum uric acid level independent of other known confounding factors affecting that level, including gender difference, eGFR, adiponectin level, VFA, and HOMA-IR.

TL;DR: Results indicate that insulin resistance is associated with plasma XOR activity and that relationship is independent of visceral adiposity and adiponectin level, suggesting that the development of insulin resistance resulting from increased visceral fat area and/or reduced serum adip onectin contributes to increased uric acid production by stimulating Xor activity.